Reports Q3 revenue $209,000, consensus $206,840. “The strength of our clinical data continues to validate our technology and reinforce our mission to redefine cancer treatment,” said Thijs Spoor, Perspective’s CEO. “With several important milestones ahead, we look forward to sharing new data and strategic updates as we close out the year and head into 2026 and beyond.”
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CATX:
- Perspective Therapeutics Updates Corporate Presentation on Pipeline
- Perspective Therapeutics Updates Executive Employment Agreements
- Perspective Therapeutics Advances in Neuroendocrine Tumor Therapy with Promising Clinical Study
- Perspective Therapeutics Advances Cancer Treatment with Innovative Clinical Study
- Perspective Therapeutics’ Innovative Melanoma Trial: A Potential Game-Changer